Sugi Predict

Sugi Predict / Compounds / SCHEMBL30924731

SCHEMBL30924731

SCHEMBL30924731

C[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CS)NC(=O)[C@H](Cc1ccccc1)NC(=O)CN)C(=O)N[C@@H](CS)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)O

nearest known ligand 0.57

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ NPY4R P50391 9/20 0.57
▸ NPY5R Q15761 8/20 0.57
▸ NPY1R P25929 7/20 0.57
▸ TFPI P10646 1/20 0.53
▸ NPY2R P49146 5/20 0.52
▸ IL23R Q5VWK5 6/20 0.51
▸ QRFPR Q96P65 1/20 0.50
▸ EPHA2 P29317 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30924745 1.00 NPY4R (0.57) NPY4RNPY5RNPY1RTFPINPY2R
SCHEMBL30924741 0.97 TFPI (0.57) NPY4RNPY5RNPY1RTFPINPY2R
SCHEMBL30924739 0.96 QRFPR (0.53) NPY4RNPY5RNPY1RTFPINPY2R
SCHEMBL30924734 0.93 IL23R (0.57) NPY4RNPY5RNPY1RTFPINPY2R
SCHEMBL30924743 0.89 TFPI (0.56) NPY4RNPY5RNPY1RTFPINPY2R
SCHEMBL29375862 0.87 NPY4R (0.62) NPY4RNPY5RNPY1RTFPINPY2R
SCHEMBL29679859 0.87 TFPI (0.56) NPY4RNPY5RNPY1RTFPIEPHA2
SCHEMBL31688334 0.87 OPRD1 (0.57) NPY4RNPY5RNPY1RTFPIIL23R
SCHEMBL30924738 0.86 NPY4R (0.62) NPY4RNPY5RNPY1RTFPINPY2R
SCHEMBL29805234 0.86 QRFPR (0.58) NPY4RNPY5RNPY1RTFPINPY2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026787-A1 PEPTIDES AND METHODS FOR REDUCING SKIN PIGMENTATION GLO PHARMA, INC. 2025-01-23 — — US disclosed
US-12162956-B2 Peptides and methods for reducing skin pigmentation GLO PHARMA, INC. (US) 2024-12-10 — — US disclosed
US-20240190917-A1 PEPTIDES AND METHODS FOR REDUCING SKIN PIGMENTATION GLO PHARMA, INC. 2024-06-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240190917-A1 PEPTIDES AND METHODS FOR REDUCING SKIN PIGMENTATION MC1R, TYR, MC5R NPY4R 66/4885NPY5R 38/4885NPY1R 29/4885
US-12162956-B2 Peptides and methods for reducing skin pigmentation MC1R, TYR, MC5R NPY4R 66/4885NPY5R 38/4885NPY1R 29/4885
US-20250026787-A1 PEPTIDES AND METHODS FOR REDUCING SKIN PIGMENTATION MC1R, TYR, MC5R NPY4R 66/4885NPY5R 38/4885NPY1R 29/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback